By 5 Towns Central Staff

MANHATTAN, N.Y. (July 14, 2026) — A federal appellate court has reinstated over five hundred personal injury lawsuits alleging that prenatal exposure to popular over-the-counter acetaminophen products, including Tylenol, contributed to developmental conditions such as autism spectrum disorder and attention deficit hyperactivity disorder.

The decision by the United States Court of Appeals for the Second Circuit vacates a previous lower court ruling that had effectively dismissed the consolidated multidistrict litigation. The three-judge appellate panel determined that the trial judge exceeded discretionary boundaries when disqualifying key medical and scientific experts presented by the families seeking damages. By determining that the lower court applied overly restrictive standards to the testimony of several qualified researchers, the appellate decision clears the way for the complex cases to return to the district court for further evidentiary proceedings.

Judges on the appellate panel explicitly emphasized that the procedural ruling does not constitute a finding on whether a direct medical link actually exists between prenatal acetaminophen usage and neurodevelopmental diagnoses. The court made no determinations regarding public health guidelines or product labeling mandates.

Major medical associations and leading health organizations maintain that comprehensive scientific reviews have failed to establish a proven causal connection between acetaminophen and childhood developmental conditions. Healthcare professionals continue to recommend the medication as the safest option for managing fever and pain during pregnancy when used according to standard medical guidance.

Corporate representatives for the product’s manufacturer reiterated that the recent ruling centers strictly on courtroom procedures regarding expert testimony rather than the underlying scientific facts. Defense teams expressed confidence in the medical consensus supporting the drug’s safety profile and confirmed plans to continue contesting the claims as the litigation resumes in federal court.